<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477384</url>
  </required_header>
  <id_info>
    <org_study_id>8mm-TIPS</org_study_id>
    <nct_id>NCT02477384</nct_id>
  </id_info>
  <brief_title>8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding</brief_title>
  <official_title>Randomised Trial of 8mm Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Propranolol for Prevention of Variceal Rebleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to conduct a prospective randomized trial to compare TIPS with 8mm
      expanded polytetrafluoroethylene(ePTFE)-covered stents and endoscopic variceal ligation plus
      propranolol for the prevention of recurrent esophageal variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the prevention of recurrent esophageal variceal bleeding, previous clinical studies and
      meta-analysis show that patients treated with transjugular intrahepatic portosystemic shunt
      (TIPS) have lower rebleeding rates compared with endoscopic therapy. However, TIPS is
      associated with higher rates of portosystemic encephalopathy and does not show survival
      benefit. TIPS with a small-diameter may achieve sufficient portal decompression and reduce
      the incidence of hepatic encephalopathy. The aim of this study was to conduct a prospective
      randomized trial to compare TIPS with 8mm ePTFE-covered stents and endoscopic variceal
      ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal rebleeding rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improving or worsening hepatic function</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIPS dysfunction rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of complications</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improving or worsening quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>8mm-TIPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVL plus propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>8mm-TIPS</intervention_name>
    <arm_group_label>8mm-TIPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic variceal ligation</intervention_name>
    <arm_group_label>EVL plus propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <arm_group_label>EVL plus propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>8mm ePTFE-covered stent</intervention_name>
    <arm_group_label>8mm-TIPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cirrhosis

          2. Patients who had bled from esophageal varices (≥5days and ≤28days)

          3. Child-Pugh B or Child-Pugh C≤13

        Exclusion Criteria:

          1. THE presence of gastric varices

          2. Non-cirrhotic portal hypertension

          3. Portal vein thrombosis

          4. The history of hepatic encephalopathy

          5. Total bilirubin ≥51.3 umol/L

          6. Previous treatment of TIPS or surgery

          7. Proven malignancy including hepatocellular carcinoma

          8. Contraindications to TIPS、EVL or propranolol

          9. End-stage renal disease under renal replacement therapy;

         10. Cardiorespiratory failure

         11. Pregnancy or patients not giving informed consent for endoscopic procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefeng Luo, MD</last_name>
      <phone>862885422389</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>luo xuefeng</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

